Vesicare Indication
Vesicare (solifenacin succinate) is indicated for the treatment of adults with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency 1.
Mechanism and Drug Class
Vesicare is a muscarinic (M3) receptor antagonist that works by blocking acetylcholine receptors in the detrusor muscle of the bladder, thereby reducing involuntary bladder contractions 1. This antimuscarinic mechanism specifically targets the M3 receptors responsible for bladder smooth muscle contraction, providing bladder-selective action.
Clinical Context from Guidelines
The 2019 AUA/SUFU guidelines position solifenacin as a second-line pharmacologic treatment for overactive bladder in adults 2. The guidelines emphasize that:
- Solifenacin can be used as monotherapy at 5 mg once daily (starting dose) or 10 mg once daily if well tolerated
- Combination therapy with mirabegron (a β3-adrenoceptor agonist) may be considered for patients refractory to monotherapy, with the strongest evidence supporting solifenacin 5 mg plus mirabegron 50 mg 2
Specific Symptoms Addressed
Vesicare effectively treats the core symptom triad of OAB:
- Urge urinary incontinence - involuntary urine leakage associated with urgency
- Urgency - sudden compelling desire to urinate that is difficult to defer
- Urinary frequency - voiding more than 8 times per 24 hours
The drug also demonstrates efficacy for nocturia (nighttime urination), particularly at the 10 mg dose 3.
Dosing Considerations
- Standard starting dose: 5 mg once daily
- Maximum dose: 10 mg once daily if 5 mg is well tolerated 1
- Do not exceed 5 mg in patients with severe renal impairment (CrCl <30 mL/min), moderate hepatic impairment (Child-Pugh B), or those taking strong CYP3A4 inhibitors 1
Important Contraindications
Vesicare is contraindicated in patients with 1:
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Hypersensitivity to solifenacin or any component
Clinical Efficacy Evidence
Research demonstrates that solifenacin significantly improves all major OAB symptoms compared to placebo, with approximately 50% of incontinent patients achieving complete continence after 12 weeks of treatment 3. The drug provides 24-hour symptom control with once-daily dosing and has been studied in over 2.2 million patients worldwide 4.
Common pitfall: Do not use Vesicare in patients with clinically significant bladder outlet obstruction or decreased gastrointestinal motility, as it can worsen urinary retention and constipation 1.